Shuttle Pharmaceuticals Holdings, Inc. announced that the Company, through its manufacturing partner TCG GreenChem has successfully completed the initial manufacturing campaign for the active pharmaceutical ingredient (API) of Ropidoxuridine for use in the Company?s upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. In addition, Shuttle?s recent request for a Type B pre-IND meeting with the FDA for guidance on the proposed Phase II clinical trial has been approved with a goal of receiving written responses from the FDA by September 18, 2023. With this, the Company believes it remains on track to commence its Phase II clinical study in the fourth quarter of 2023.